By NewsDesk @bactiman63
In a follow-up on Norway’s Institute of Public Health (NIPH), or Folkehelseinstituttet (FHI) decision to put the AstraZeneca COVID-19 vaccine on pause, the NIPH will keep use of the AstraZeneca vaccine on hold in Norway and will continue a thorough review of the situation.
The European Medicines Agency (EMA) presented their assessment of the vaccine this Thursday saying the benefits of getting the COVID-19 Vaccine AstraZeneca still outweigh the risks despite possible link to rare blood clots with low blood platelets.
“We take EMA’s assessment into account. Due to the situation with several serious cases in Norway, we want to thoroughly review the situation before we make a conclusion. This will take some time, and we will provide an update at the end of next week,” says Geir Bukholm, Director of the Division of Infection Control at the NIPH.
The NIPH is asking anyone who has had the AstraZeneca vaccine and who feels unwell over time, has unusual bruising or signs of bleeding in the skin or other signs of serious illness to contact the health service for an assessment. The patients who had severe blood clots, hemorrhages and low platelet counts developed symptoms within 14 days of vaccination.
- Sweden: Yersinia enterocolitica outbreak over, Iceberg lettuce is the suspected source
- Non-Viral hepatitis cases possibly linked to Bottled Alkaline Water
- UK variant of SARS-CoV-2 spread rapidly in care homes in England in November and December last year
- Colorado: Suspected norovirus increases reported in Mesa County child care centers
- Sweden pauses use of AstraZeneca’s COVID-19 vaccine pending investigation
- Ebola in DRC: 1500 vaccinated, Healthcare providers threaten strike
